About Fresenius Kabi Pharmaceuticals Holding, Inc. / APP Pharmaceuticals, Inc.
Fresenius Kabi Pharmaceuticals Holding, Inc., a wholly owned subsidiary of Fresenius Kabi AG, acquired APP Pharmaceuticals, Inc. on September 10, 2008. APP Pharmaceuticals, Inc. is a fully-integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. The company offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. For more information about APP Pharmaceuticals, Inc., please visit the company's Web site at www.APPpharma.com.
As of December 31, 2009, we had a total of 1,615 full-time employees, of which 65 were engaged in research and development, 411 were in quality assurance and quality control, 843 were in manufacturing, 96 were in sales and marketing and 200 were in administration and finance. None of our employees are represented by a labor union or subject to a collective bargaining agreement. We have not experienced any work stoppage and consider our relations with our employees to be good.
10-29-2010 APP Pharma cleared by FDA for hypertension drug
TEL AVIV (MarketWatch) -- APP Pharmaceuticals Inc., the Schaumburg, Ill., drugmaker, was cleared by the U.S. Food and Drug Administration to market chlorothiazide sodium injection to treat high blood pressure as well as fluid retention for patients with congestive heart failure, cirrhosis of the liver and other ailments. The drug is a generic equivalent to Diuril, which is produced by Lundbeck Pharmaceuticals. /quotes/comstock/11i!hluky (HLUK.Y 18.19, +0.04, +0.22%) APP Pharma is a subsidiary of Fresenius Kabi Pharmaceuticals Holding Inc.
3-19-2010 APP Pharmaceuticals is owned by Fresenius and received FDA approval for their injectable intravenous generic indomethacin late Friday
Here is the link to the FDA website: http://www.fda.gov/Drugs/NewsEvents/ucm1...
|The CVRs |
In connection with the Merger, each APP shareholder was issued one contingent value right of FKP Holdings. The CVRs are intended to give holders an opportunity to participate in any excess Adjusted EBITDA, as defined in the CVR Indenture, generated during the three years ending December 31, 2010, referred to as the “CVR measuring period,” in excess of a threshold amount. Each CVR represents the right to receive a pro rata portion of an amount equal to 2.5 times the amount by which cumulative Adjusted EBITDA of APP and FKP Holdings and their subsidiaries on a consolidated basis, exceeds $1.267 billion for the three years ending December 31, 2010. The maximum amount payable under the CVR Indenture is $6.00 per CVR
Fresenius Kabi Pharmaceuticals Holding, Inc. Files Form 10-K For APP Pharmaceuticals, Inc. (APP)
SCHAUMBURG, ILL.--(BUSINESS WIRE)--
Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) today filed its Form 10-K for APP which provides an update on the Contingent Value Rights (CVRs) granted to APP stockholders in September 2008 in conjunction with Fresenius Kabi Pharmaceuticals Holding's acquisition of APP.
Pursuant to the agreement governing the CVRs, the right to receive a payment with respect to the CVRs was contingent upon APP achieving consolidated cumulative Adjusted EBITDA in excess of $1.268 billion for the measurement period (three years ending December 31, 2010). The consolidated Adjusted EBITDA for the measurement period was $1.126 billion. Since the cumulative Adjusted EBITDA did not exceed the required threshold, CVR holders will not receive any payments on the CVRs and the CVRs will expire without value.
The company will give formal notice to the NASDAQ Capital Market of its intention to deregister under the Securities Exchange Act of 1934 (the "Exchange Act") and delist the CVRs from the NASDAQ. The Company will also terminate its obligation to file periodic reports, such as a Form 10-K, Form 10-Q or Form 8-K, under the Exchange Act. It is expected that the CVRs will cease trading on NASDAQ on March 4, 2011. The delisting is expected to be made effective by the NASDAQ prior to the end of the first quarter 2011
AFTER HOUR TRADES --> www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx